Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Mural Oncology plc - Ordinary Shares (NQ:MURA)

2.099 -0.001 (-0.06%)
Streaming Delayed Price Updated: 1:31 PM EDT, Oct 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Mural Oncology plc - Ordinary Shares

< Previous 1 2 Next >
Traders are paying attention to the gapping stocks in Wednesday's session.
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Wednesday. 
Via Chartmill
Mural Oncology To Be Acquired By Xoma Royalty
Via Stocktwits
Unusual volume stocks in Monday's session
Let's have a look at what is happening on the US markets on Monday. Below you can find the stocks with an unusual volume in today's session. 
Via Chartmill
Mural Oncology (MURA) Q2 Loss Widens 49%
Via The Motley Fool
These stocks are moving in today's pre-market session
As we await the opening of the US market on Wednesday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment. 
Via Chartmill
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
Mural Oncology's Retail Buzz Explodes After Micro-Cap Biotech Mulls Strategic Alternatives
The company will cut approximately 90% of its workforce as part of the strategic shift. 
Via Stocktwits
Top stock movements in today's session.
Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes. 
Via Chartmill
Curious about the most active stocks on Tuesday?
Curious about the most active stocks on Tuesday? Find out which stocks are dominating the market action! 
Via Chartmill
Mural Oncology Shares Surge As Company Explores Strategic Alternatives: What's Going On?
Shares of Mural Oncology plc (NASDAQ: MURA) are soaring Monday following the company's announcement that it will discontinue clinical development of its lead drug candidate Nemvaleukin and begin... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
 
Via Benzinga
The market is filled with gapping stocks in Tuesday's session.
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Tuesday. 
Via Chartmill
Crude Oil Moves Lower; Citigroup Posts Upbeat Results
 
Via Benzinga
Stay updated with the stocks that are on the move in today's pre-market session.
Before the US market kicks off on Tuesday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers. 
Via Chartmill
Nasdaq Surges 100 Points; Bank of America Earnings Top Views
 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
Top movers analysis one hour before the close of the markets on 2025-03-25: top gainers and losers in today's session.
Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes. 
Via Chartmill
Which stocks are experiencing notable movement on Tuesday?
Keep an eye on the top gainers and losers in Tuesday's session, as they reflect the most notable price movements. 
Via Chartmill
12 Health Care Stocks Moving In Tuesday's Intraday Session
 
Via Benzinga
Let's uncover which stocks are experiencing notable gaps during today's session.
The market is buzzing with gapping stocks on Tuesday. Let's uncover which stocks are experiencing notable gaps during today's session. 
Via Chartmill
Nasdaq Gains 50 Points; US New Home Sales Rise In February
 
Via Benzinga
Which stocks are moving before the opening bell on Tuesday?
Before the US market kicks off on Tuesday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers. 
Via Chartmill
US Stocks Mixed; Core & Main Posts Downbeat Earnings
 
Via Benzinga
Mural Oncology's Ovarian Cancer Combo Drug Trial Disappoints, Stock Plunges
Mural Oncology ends nemvaleukin development for ovarian cancer after ARTISTRY-7 trial misses survival goals. Phase 2 trials for melanoma continue into 2025. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
Why Power Solutions International Shares Are Trading Higher By Around 10%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
This Vital Farms Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
This MINISO Group Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.